Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EuroinvestmentWAR:VIV -2.27% Equity-to-Asset is -40.38 as of Jun. 2026. Among 211 Medical Diagnostics & Research companies, Euroinvestment ranks worse than 99.53% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Euroinvestment's Total Stockholders Equity for the quarter that ended in Jun. 2026 was zł-2.99 Mil. Euroinvestment's Total Assets for the quarter that ended in Jun. 2026 was zł0.07 Mil.
The historical rank and industry rank for Euroinvestment's Equity-to-Asset or its related term are showing as below:
WAR:VIV'
s Equity-to-Asset Range Over the Past 10 Years
Min: -340.83 Med: -62.27 Max: -4.72
Current: -40.43
During the past 13 years, the highest Equity to Asset Ratio of Euroinvestment was -4.72. The lowest was -340.83. And the median was -62.27.
WAR:VIV's Equity-to-Asset is ranked worse than 99.53% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs WAR:VIV: -40.43
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Euroinvestment Equity-to-Asset Related Terms
Euroinvestment Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Euroinvestment's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:VIV vs TMO, DHR, NTRA: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Euroinvestment's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euroinvestment Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Euroinvestment's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Euroinvestment's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Euroinvestment's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euroinvestment (WAR:VIV) has a Equity-to-Asset of -40.38 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Euroinvestment and its competitors. According to the industry distribution chart, Euroinvestment ranks #210 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 99.5%.
Is Euroinvestment's Equity-to-Asset too high?
Euroinvestment's current Equity-to-Asset is -40.38. Based on the distribution chart, Euroinvestment ranks #210 out of 211 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Euroinvestment's Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Euroinvestment ranks #210 out of 211 companies for Equity-to-Asset. This places Euroinvestment in the lower half of its industry. The industry median Equity-to-Asset is 0.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Euroinvestment and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euroinvestment's current Equity-to-Asset is -40.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euroinvestment stock overvalued right now?
Euroinvestment (WAR:VIV) has a current Equity-to-Asset of -40.38. The current Equity-to-Asset is -40.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Euroinvestment (WAR:VIV), the current Equity-to-Asset is -40.38 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Euroinvestment SA is a holding company. It is engaged in providing dental and prosthetic laboratory services. It serves through a network of 6 clinics in Warsaw, Poland.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:VIV has been successfully added to your 
